ClinicalTrials.gg
Sign In

Meibomian Gland Dysfunction clinical trials

The registry lists 172 studies for Meibomian Gland Dysfunction across more than 10 countries. 23 are recruiting or about to start. 103 of them are mainly about Meibomian Gland Dysfunction (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Meibomian Gland Dysfunction studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
105
Status unknown
29
Recruiting
13
Withdrawn
9
Not yet recruiting
7
Active, not recruiting
4

Phase

Phase 2
19
Phase 4
17
Phase 3
6
Phase 1
2
Early Phase 1
1

Where

United States
63
China
20
Spain
7
Canada
6
Thailand
6
United Kingdom
6

Who runs them

University of the Incarnate Word (5) · Lumenis Be Ltd. (5) · Chulalongkorn University (5) · Yonsei University (5) · Aston University (4) · Azura Ophthalmics (4) · Sight Sciences, Inc. (3) · Tear Film Innovations, Inc. (3)

What is being tested here

Drugs under test in Meibomian Gland Dysfunction studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Cyclosporine101
Varenicline101
Azithromycin004
Hyaluronic Acid022
Loteprednol Etabonate002
Carboxypolymethylene002
Isotretinoin001
TP-03001
Dexamethasone001
Minocycline001

Coming up

0phase 3 studies under way
12studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 13 Meibomian Gland Dysfunction studies recruiting now, 10 (77%) set no upper age limit and 1 (8%) stop at 75 or younger. 1 (8%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (8%) take healthy volunteers.

Recruiting studies that take each age, of 13
AgeWomenMen
101 (8%)1 (8%)
1810 (77%)10 (77%)
3011 (85%)11 (85%)
4011 (85%)11 (85%)
5013 (100%)13 (100%)
6513 (100%)13 (100%)
7513 (100%)13 (100%)
8511 (85%)11 (85%)

Across all 172 studies, recruiting or not: 16% stop at 75 or younger and 10% at 65; 6% take children; 3% are for women only and 0% for men only; 24% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Meibomian Gland Dysfunction studies take

Of 74 interventional studies with no phase under Meibomian Gland Dysfunction, half reached primary completion within 11 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase11 mo5–19 · 74 studies9 mo2–15 · 22 studies11 mo5–27 · 52 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 172. Browse all 172 → or search them.